Context Therapeutics Inc (CNTX)
$1.56
Live
Insights on Context Therapeutics Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 72.6% return, outperforming this stock by 13.2%
Performance
- $1.56$2.02$1.56
0.0%
Downside
Day's Volatility :22.77%
Upside
22.77%
- $0.77$2.12$1.56
50.64%
Downside
52 Weeks Volatility :63.68%
Upside
26.42%
Returns
| Period | Context Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 78.95% | 0.0% |
6 Months | 121.45% | 0.0% |
1 Year | 82.14% | 0.0% |
3 Years | -60.0% | -22.6% |
Highlights
Market Capitalization | 148.5M |
Book Value | $0.53 |
Earnings Per Share (EPS) | -1.33 |
Wall Street Target Price | 5.4 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -64.59% |
Return On Equity TTM | -114.72% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -22.2M |
Diluted Eps TTM | -1.33 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.69 |
EPS Estimate Next Year | -0.32 |
EPS Estimate Current Quarter | -0.44 |
EPS Estimate Next Quarter | -0.13 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 246.15%
Technicals Summary
Sell
Neutral
Buy
Context Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Context Therapeutics Inc | 14.61% | 121.45% | 82.14% | -60.0% | -60.0% |
 Moderna, Inc. | 21.03% | 85.08% | 14.68% | -28.27% | 659.22% |
 Regeneron Pharmaceuticals, Inc. | 3.22% | 20.18% | 31.88% | 93.3% | 227.58% |
 Novo Nordisk A/s | 8.85% | 34.38% | 71.83% | 235.07% | 463.44% |
 Vertex Pharmaceuticals Incorporated | 16.81% | 34.1% | 40.6% | 123.97% | 174.53% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Context Therapeutics Inc | NA | NA | NA | -0.69 | -1.15 | -0.65 | NA | 0.53 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Context Therapeutics Inc | Buy | $148.5M | -60.0% | NA | 0.0% |
Moderna, Inc. | Buy | $54.6B | 659.22% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 227.58% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 463.44% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 174.53% | 29.59 | 39.46% |
Institutional Holdings
Opaleye Management Inc
1.48%Ally Bridge Group (NY) LLC
0.97%Vanguard Group Inc
0.80%Affinity Asset Advisors, LLC
0.44%UBS O'Connor LLC
0.40%HighTower Advisors, LLC
0.17%
Company Information
context therapeutics is dedicated to discovering, acquiring, and developing novel compounds to treat hormone responsive cancers. our lead program is apristor (onapristone xr), an investigational drug for progesterone receptor positive (pr+) breast cancer. up to 70% of breast cancers express progesterone receptor (pr). if your cancer is pr+, apristor could be an option for you.
Organization | Context Therapeutics Inc |
Employees | 5 |
CEO | Mr. Martin A. Lehr |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$1.56
-23.53%
Keyarch Acquisition Corp
$1.56
-23.53%
Connexa Sports Technologies Inc
$1.56
-23.53%
Us Value Etf
$1.56
-23.53%
First Wave Biopharma Inc
$1.56
-23.53%
Global X Msci Next Emerging
$1.56
-23.53%
Fat Projects Acquisition Corp
$1.56
-23.53%
Capital Link Global Fintech
$1.56
-23.53%
Applied Uv Inc
$1.56
-23.53%